Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor, currently in phase III development for primary hypercholesterolaemia or mixed dyslipidaemia, including reduction in cardiovascular mortality and morbidity in patients at high risk of CV events, in combination with a statin.
Patients in this study were assigned to either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). All patients were also receiving intensive atorvastatin therapy. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.